| ABSTRACT Nowadays, systemic lupus erythematosus is a challenging autoimmune disease with multiorgan dysfunction induced by diverse autoantibodies, and the strategy of B cell targeted therapy, which including B cell depletion and inhibition of B cell activating factor, is not only the hotspot, but also the difficult viewpoint on acute critical and refractory cases in clinic. Moreover, in spite of rituximab and belimumab being efficacy and safety in common, but all the others are being in animal researches and clinical trials. In the future, based on multicenter studies, we should pay more attention in selections of ideal cases, therapeutic drugs, time window of initial treatment and end point of clinical trial. |
